JERUSALEM (AP) _ Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported a loss of $4.4 million in its fiscal third quarter.
The Jerusalem-based company said it had a loss of 30 cents per share.
The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.
The drug maker posted revenue of $617,000 in the period, meeting Street forecasts.
Oramed shares have declined 33 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.99, a fall of 28 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORMP at https://www.zacks.com/ap/ORMP
Automated Insights, source Associated Press News